SCHEMBL4772092

SCHEMBL4772092

CN1C(=O)Cc2cncnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.35
CYP2D6 P10635 9/20 0.35
CYP1A2 P05177 8/20 0.35
CYP2C19 P33261 6/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
BMPR1B O00238 7/20 0.34
BMPR1A P36894 7/20 0.34
ACVRL1 P37023 7/20 0.34
ACVR1 Q04771 7/20 0.34
HSD17B10 Q99714 4/20 0.34
TSHR P16473 2/20 0.34
ALOX15 P16050 2/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
IDH1 O75874 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
TGFBR1 P36897 3/20 0.32
CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853911 1.00 CYP3A4 (0.35) CYP3A4CYP2D6CYP1A2CYP2C19MEN1
SCHEMBL12339196 0.77 BMPR1B (0.38) CYP3A4CYP2D6CYP1A2CYP2C19MEN1
SCHEMBL6070753 0.75 CYP2D6 (0.35) CYP3A4CYP2D6CYP1A2CYP2C19MEN1
SCHEMBL8629038 0.73 CYP11B2 (0.36) MEN1KMT2ABMPR1BBMPR1AACVRL1
SCHEMBL30661603 0.71 CYP11B2 (0.36) BMPR1BBMPR1AACVRL1ACVR1IDH1
SCHEMBL18168138 0.71 SMN1; SMN2 (0.44) MEN1KMT2ABMPR1BBMPR1AACVRL1
SCHEMBL8137963 0.71 HSD17B10 (0.41) BMPR1BBMPR1AACVRL1ACVR1HSD17B10
SCHEMBL26621580 0.71 CYP11B2 (0.36) BMPR1BBMPR1AACVRL1ACVR1IDH1
SCHEMBL8630032 0.71 MAPT (0.38) BMPR1BBMPR1AACVRL1ACVR1CYP11B2
SCHEMBL18422666 0.71 LMNA (0.35) MEN1KMT2AALDH1A1BMPR1BBMPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994555-B2 Chromenone inhibitors of monocarboxylate transporters THE SCRIPPS RESEARCH INSTITUTE (US) 2018-06-12 US disclosed
US-20180009792-A1 CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS THE SCRIPPS RESEARCH INSTITUTE (US) 2018-01-11 US disclosed
US-20180008605-A1 PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2018-01-11 US disclosed
US-20180002343-A1 HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2018-01-04 US disclosed
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2017-07-20 US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 WO disclosed
EP-0257102-B1 AGENTS FOR TREATING NEUROPHATHY MITSUI PETROCHEMICAL IND (JP) 1997-11-19 EP disclosed
EP-0799617-A2 Therapeutic agent for neurological diseases MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1997-10-08 EP disclosed
US-4959368-A PYRIMIDINE DERIVATIVES MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1990-09-25 US disclosed
EP-0257102-A1 AGENTS FOR TREATING NEUROPHATHY Mitsui Chemicals, Inc. (JP) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002343-A1 HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS SLC16A1, SLC16A3, SLC16A7 CYP3A4 825/4885CYP2D6 1755/4885CYP1A2 1915/4885
US-20180009792-A1 CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS SLC16A3, SLC16A1, SLC16A7 CYP3A4 311/4885CYP2D6 1570/4885CYP1A2 1020/4885
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT CYP3A4 2699/4885CYP2D6 2628/4885CYP1A2 3086/4885
US-20180008605-A1 PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS SLC16A1, SLC16A3, SLC16A7 CYP3A4 1085/4885CYP2D6 2453/4885CYP1A2 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.